TransMedics grants stock options and restricted units to 14 new employees as hiring incentives

TransMedics Group, a medical tech company specializing in organ transplant therapies, granted stock options for 37,367 shares and 24,848 restricted stock units to 14 new employees on May 19, 2026. These grants serve as inducements for employment and include significant awards to Senior VP Matthew S. Forsyth. The stock options have a 10-year term with vesting over four years, and the restricted stock units also vest over four years. This move aims to attract and retain talent critical to advancing TransMedics' mission to improve organ transplant outcomes.